Sugi Predict

Sugi Predict / Compounds / SCHEMBL841973

SCHEMBL841973

SCHEMBL841973

N[C@@H]1CN(C(=O)O)C[C@H]1O

nearest known ligand 0.36

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GABRR1 P24046 1/20 0.33
▸ SLC6A12 P48065 2/20 0.30
▸ SLC6A11 P48066 2/20 0.30
▸ SLC6A13 Q9NSD5 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL745985 1.00 GABRR1 (0.33) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL505726 1.00 GABRR1 (0.33) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL4609252 1.00 GABRR1 (0.33) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL18555595 1.00 GABRR1 (0.33) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL5403763 1.00 GABRR1 (0.33) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL18957048 1.00 GABRR1 (0.33) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL4627762 0.85 GABRR1 (0.39) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL3620776 0.85 GABRR1 (0.39) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL3620778 0.85 GABRR1 (0.39) GABRR1SLC6A12SLC6A11SLC6A13
SCHEMBL19816446 0.85 GABRR1 (0.39) GABRR1SLC6A12SLC6A11SLC6A13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4370514-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS F. Hoffmann-La Roche AG (CH) 2024-05-22 — — EP disclosed
WO-2024091511-A1 HETEROCYCLIC TEAD INHIBITORS LIGHT HORSE THERAPEUTICS, INC. (US) 2024-05-02 — — WO disclosed
US-11926613-B2 Kinase inhibitors for the treatment of central and peripheral nervous system disorders UNIVERSITY OF MIAMI (US) 2024-03-12 — — US disclosed
US-11858912-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-01-02 — — US disclosed
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 — — US disclosed
WO-2023177233-A1 NOVEL COMPOUND AND USE THEREOF FOR INHIBITING CHECKPOINT KINASE 2 (주)아름테라퓨틱스 2023-09-21 — — WO disclosed
US-20230133845-A1 NOVEL HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2023-05-04 — — US disclosed
EP-4169575-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS Sato Pharmaceutical Co., Ltd. (JP) 2023-04-26 — — EP disclosed
WO-2023285497-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS F. HOFFMANN-LA ROCHE AG (CH) 2023-01-19 — — WO disclosed
US-20220402869-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-22 — — US disclosed
US-20050038040-A1 Compounds as CRF1 receptor antagonists PFIZER INC 2005-02-17 — — US disclosed
WO-2004099201-A1 COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-11-18 — — WO disclosed
US-20040224961-A1 Novel thiazolo (4,5-D) pyrimidine compounds ASTRAZENECA UK LIMITED, A BRITISH CORPORATION 2004-11-11 — — US disclosed
EP-1446387-A1 SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2004-08-18 — — EP disclosed
US-6767910-B1 ANTICOAGULANTS ASTRAZENECA AB (SE) 2004-07-27 — — US disclosed
EP-1216248-B1 TRIAZOLOPYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2004-02-18 — — EP disclosed
US-20030144297-A1 Substituted aryl 1,4-pyrazine derivatives PHARMACIA & UPJOHN COMPANY 2003-07-31 — — US disclosed
WO-2003045924-A1 SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-06-05 — — WO disclosed
EP-1216248-A2 TRIAZOLOPYRIMIDINE DERIVATIVES AstraZeneca AB (SE) 2002-06-26 — — EP disclosed
WO-2001019826-A2 TRIAZOLOPYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2001-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858912-B2 Heterocyclic compounds F12, C1R, MRPL21 GABRR1 2322/4885SLC6A12 3313/4885SLC6A11 3146/4885
US-20040224961-A1 Novel thiazolo (4,5-D) pyrimidine compounds TYMS, DPYD, TYMP GABRR1 4625/4885SLC6A12 1340/4885SLC6A11 1683/4885
US-20050038040-A1 Compounds as CRF1 receptor antagonists CRHR1, CRHR2, CRH GABRR1 324/4885SLC6A12 800/4885SLC6A11 178/4885
US-20230133845-A1 NOVEL HETEROCYCLIC COMPOUNDS F12, PM20D2, XDH GABRR1 1881/4885SLC6A12 3194/4885SLC6A11 3055/4885
US-20220402869-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 GABRR1 4755/4885SLC6A12 1965/4885SLC6A11 1619/4885
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS HPGDS, PTGS1, PTGIS GABRR1 1461/4885SLC6A12 4551/4885SLC6A11 3292/4885
US-11926613-B2 Kinase inhibitors for the treatment of central and peripheral nervous system disorders PNCK, PYGB, PMP22 GABRR1 376/4885SLC6A12 3150/4885SLC6A11 1099/4885
US-20030144297-A1 Substituted aryl 1,4-pyrazine derivatives HTR2C, HTR4, HTR5A GABRR1 604/4885SLC6A12 2187/4885SLC6A11 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.